Calamos Wealth Management LLC purchased a new position in shares of Synopsys, Inc. (NASDAQ: SNPS) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 21,555 shares of the semiconductor company's stock, valued at approximately $10,635,000. Other hedge funds also recently modified their holdings of
PHILADELPHIA, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
NEW YORK, Dec. 30, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Synopsys, Inc. ("Synopsys, Inc." or the "Company") (NASDAQ: SNPS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Synopsys, Inc. investors who were adversely affected by alleged securities fraud between December 4, 2024 and September 9, 2025.
/PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Synopsys, Inc. (NASDAQ: SNPS) between December 4,
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Synopsys, Inc. ("Synopsys, Inc." or the "Company") (NASDAQ: SNPS) of a class action securities lawsuit.
/PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Synopsys, Inc. ("Synopsys" or the "Company") (NASDAQ: SNPS)
New York, New York--(Newsfile Corp. - December 29, 2025) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Synopsys, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit.
LOS ANGELES, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Synopsys to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Synopsys between December 4, 2024 and September 9, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 29, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Synopsys, Inc. ("Synopsys" or the "Company") (NASDAQ: SNPS) and reminds investors of the December 30, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
LOS ANGELES, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Synopsys, Inc. (“Synopsys” or “the Company”) (NASDAQ: SNPS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 4, 2024 and September 9, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 30, 2025.
